CN110869378B - 预防和治疗疾病的化合物及其用途 - Google Patents

预防和治疗疾病的化合物及其用途 Download PDF

Info

Publication number
CN110869378B
CN110869378B CN201880045752.6A CN201880045752A CN110869378B CN 110869378 B CN110869378 B CN 110869378B CN 201880045752 A CN201880045752 A CN 201880045752A CN 110869378 B CN110869378 B CN 110869378B
Authority
CN
China
Prior art keywords
group
substituted
galectin
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880045752.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110869378A (zh
Inventor
E·佐默
P·G·特拉伯
R·尼尔
S·谢克特尔
J·M·约翰逊
R·乔治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Sciences LLC
Original Assignee
Galectin Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences LLC filed Critical Galectin Sciences LLC
Publication of CN110869378A publication Critical patent/CN110869378A/zh
Application granted granted Critical
Publication of CN110869378B publication Critical patent/CN110869378B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
CN201880045752.6A 2017-05-12 2018-05-11 预防和治疗疾病的化合物及其用途 Active CN110869378B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
US62/505,544 2017-05-12
PCT/US2018/032349 WO2018209255A1 (en) 2017-05-12 2018-05-11 Compounds for the prevention and treatment of diseases and the use thereof

Publications (2)

Publication Number Publication Date
CN110869378A CN110869378A (zh) 2020-03-06
CN110869378B true CN110869378B (zh) 2023-10-13

Family

ID=64105444

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880045752.6A Active CN110869378B (zh) 2017-05-12 2018-05-11 预防和治疗疾病的化合物及其用途

Country Status (12)

Country Link
US (2) US11576924B2 (https=)
EP (1) EP3621973A4 (https=)
JP (1) JP7204676B2 (https=)
KR (1) KR102626669B1 (https=)
CN (1) CN110869378B (https=)
AU (1) AU2018265571B2 (https=)
BR (1) BR112019023722A2 (https=)
CA (1) CA3062648A1 (https=)
IL (1) IL270469B2 (https=)
MX (1) MX392945B (https=)
WO (1) WO2018209255A1 (https=)
ZA (1) ZA201908165B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022511094A (ja) 2018-12-06 2022-01-28 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
CN118373810A (zh) * 2018-12-27 2024-07-23 糖模拟物有限公司 抑制c-糖苷的半乳凝素-3
EP3947407B1 (en) * 2019-03-26 2024-06-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
EP3953349A1 (en) 2019-04-10 2022-02-16 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
EP4010348B1 (en) 2019-08-09 2023-12-20 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体
CA3148365A1 (en) 2019-08-29 2021-03-04 Martin Bolli Alpha-d-galactopyranoside derivatives
CA3161794A1 (en) * 2019-12-24 2021-07-01 John L. Magnani Galectin-3 inhibiting c-glycoside ketones, ethers, and alcohols
KR20230006547A (ko) * 2020-05-05 2023-01-10 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
EP4149939A1 (en) 2020-05-11 2023-03-22 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
EP4157833A1 (en) 2020-05-28 2023-04-05 Bristol-Myers Squibb Company Galectin-3 inhibitors
ES3014851T3 (en) * 2020-10-06 2025-04-25 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
KR20230104190A (ko) 2020-11-02 2023-07-07 이도르시아 파마슈티컬스 리미티드 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체
KR20230145111A (ko) * 2021-02-09 2023-10-17 이도르시아 파마슈티컬스 리미티드 히드록시헤테로시클로알칸-카르바모일 유도체
PL4301748T3 (pl) * 2021-03-03 2025-09-08 Idorsia Pharmaceuticals Ltd Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070190A (en) * 1988-04-16 1991-12-03 Bayer Aktiengesellschaft Substituted n-glycosylamides, process for their preparation, and their use as medicaments
WO1998028318A1 (en) * 1996-12-20 1998-07-02 Oxford Glycosciences (Uk) Limited Therapeutic compounds
WO2016120403A1 (en) * 2015-01-30 2016-08-04 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN109071585A (zh) * 2016-03-04 2018-12-21 卡莱克汀科学有限责任公司 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
GB0501008D0 (en) 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
US8697862B2 (en) 2008-05-16 2014-04-15 Galecto Biotech Ab Synthesis of galactoside inhibitors
CN102439021B (zh) 2009-04-28 2015-09-02 格莱克特生物技术公司 半乳凝素的新型半乳糖苷抑制剂
BR112012008063A2 (pt) 2009-08-25 2016-11-22 Bg Medicine Inc galectina-3 e terapia de ressincronização cardíaca.
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
CA2794066C (en) 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
ES2869884T3 (es) 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
AU2012363033B2 (en) 2011-12-28 2016-06-02 Galectin Therapeutics, Inc. Composition of novel carbohydrate drug for treatment of human diseases
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
WO2014078655A1 (en) 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP2017512205A (ja) 2014-03-10 2017-05-18 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎臓障害を治療するための組成物及び方法
EP3129032A1 (en) 2014-04-08 2017-02-15 Galecto Biotech AB Galactoside inhibitors for the treatment of alpha-synucleinopthies
EP3415522A1 (en) 2014-07-09 2018-12-19 Galecto Biotech AB Novel hybrid galactoside inhibitor of galectins
WO2017019770A1 (en) 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
ES2921500T3 (es) 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
US20200061095A1 (en) 2017-05-12 2020-02-27 Galectin Sciences, Llc Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5070190A (en) * 1988-04-16 1991-12-03 Bayer Aktiengesellschaft Substituted n-glycosylamides, process for their preparation, and their use as medicaments
WO1998028318A1 (en) * 1996-12-20 1998-07-02 Oxford Glycosciences (Uk) Limited Therapeutic compounds
WO2016120403A1 (en) * 2015-01-30 2016-08-04 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN109071585A (zh) * 2016-03-04 2018-12-21 卡莱克汀科学有限责任公司 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Design of Glycosyltransferase Inhibitors: Pyridine as a Pyrophosphate Surrogate;Shuai Wang et al.;《Chem. Eur. J.》;20130923;第19卷;第15346 -15357页 *
Development of Carbohydrate-Based Scaffolds for Restricted Presentation of Recognition Groups. Extension to Divalent Ligands and Implications for the Structure of Dimerized bceptors;Paul V. Murphy et al.;《J. Org. Chem.》;20030618;第68卷;第5692-5704页 *
Utilizing Staudinger Ligation for the Synthesis of Glycoamino Acid Building Blocks and Other Glycomimetics;Alexander Schierholt et al.;《Eur. J. Org. Chem.》;20091231;第3783–3789页 *

Also Published As

Publication number Publication date
US11576924B2 (en) 2023-02-14
CN110869378A (zh) 2020-03-06
WO2018209255A1 (en) 2018-11-15
MX392945B (es) 2025-03-19
BR112019023722A2 (pt) 2020-05-26
EP3621973A1 (en) 2020-03-18
US20230132265A1 (en) 2023-04-27
CA3062648A1 (en) 2018-11-15
MX2019013537A (es) 2020-02-13
IL270469B2 (en) 2023-07-01
JP7204676B2 (ja) 2023-01-16
AU2018265571A1 (en) 2019-12-05
KR102626669B1 (ko) 2024-01-17
EP3621973A4 (en) 2021-10-27
IL270469B1 (en) 2023-03-01
AU2018265571B2 (en) 2022-09-29
IL270469A (https=) 2019-12-31
ZA201908165B (en) 2023-07-26
KR20200016246A (ko) 2020-02-14
JP2020519625A (ja) 2020-07-02
US20200155586A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
CN110869378B (zh) 预防和治疗疾病的化合物及其用途
CN111032670A (zh) 用于治疗系统性胰岛素抗性病症的化合物及其用途
WO2019089080A1 (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
CN111032039B (zh) 用于预防和治疗医学障碍的化合物及其用途
CN109071585B (zh) 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
BR112018067693B1 (pt) Selenogalactosídeos, seus usos, e composição

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant